Elite control of HIV: Is this the right model for a functional cure?

Trends in Microbiology

Volumn 23, Issue 2, 2015, Pages 71-75

  Cockerham, Leslie R ^a   Hatano, Hiroyu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; Elite controllers; HIV; Immune activation; Inflammation; Viral reservoirs

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA; VIRUS RNA;

CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE ASSOCIATION; ELITE CONTROL; HEALTH SERVICES RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFLAMMATION; NONHUMAN; REMISSION; RESEARCH PRIORITY; REVIEW; T CELL DEPLETION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION;

EID: 84964290941     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.11.003     Document Type: Review

References (58)

1. Palella F.J., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998, 338:853-860.
2. Lohse N., et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann. Intern. Med. 2007, 146:87-95.
3. Chun T.W., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
4. Phillips A.N., et al. The role of HIV in serious diseases other than AIDS. AIDS 2008, 22:2409-2418.
5. Currier J.S., et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008, 118:e29-e35.
6. Choi A.I., et al. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 2009, 23:2143-2149.
7. Triant V.A., et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J. Clin. Endocrinol. Metab. 2008, 93:3499-3504.
8. Gardner E.M., et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin. Infect. Dis. 2011, 52:793-800.
9. Piot P., Quinn T.C. Response to the AIDS pandemic - a global health model. N. Engl. J. Med. 2013, 368:2210-2218.
10. Deeks S.G., et al. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 2012, 12:607-614.
11. Hutter G., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 2009, 360:692-698.
12. Allers K., et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011, 117:2791-2799.
13. Yukl S.A., et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin Patient. PLoS Pathog. 2013, 9:e1003347.
14. Okulicz J.F., Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr. Opin. HIV AIDS 2011, 6:163-168.
15. Pereyra F., et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010, 330:1551-1557.
16. Migueles S.A., et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:2709-2714.
17. Dean M., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862.
18. Jiang Y., et al. KIR3DS1/L1 and HLA-Bw4-80I are associated with HIV disease progression among HIV typical progressors and long-term nonprogressors. BMC Infect. Dis. 2013, 13:405.
19. O'Connell K.A., et al. Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J. Virol. 2009, 83:5028-5034.
20. Emu B., et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 2008, 82:5398-5407.
21. Walker B.D., Yu X.G. Unravelling the mechanisms of durable control of HIV-1. Nat. Rev. Immunol. 2013, 13:487-498.
22. Saez-Cirion A., et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:6776-6781.
23. Migueles S.A., et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008, 29:1009-1021.
24. Betts M.R., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
25. Hersperger A.R., et al. Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr. Opin. HIV AIDS 2011, 6:169-173.
26. Hersperger A.R., et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 2010, 6:e1000917.
27. Bailey J.R., et al. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J. Exp. Med. 2006, 203:1357-1369.
28. Lambotte O., et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009, 23:897-906.
29. Doria-Rose N.A., et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 2010, 84:1631-1636.
30. Smalls-Mantey A., et al. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J. Virol. 2012, 86:8672-8680.
31. Martin M.P., et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 2007, 39:733-740.
32. Qi Y., et al. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2006, 2:e79.
33. Alter G., et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 2007, 204:3027-3036.
34. Gandhi S.K., et al. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J. Virol. 2008, 82:3125-3130.
35. Abdel-Mohsen M., et al. Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology 2013, 10:106.
36. Shan L., et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36:491-501.
37. Pereyra F., et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J. Infect. Dis. 2009, 200:984-990.
38. Hatano H., et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 2010, 24:2535-2539.
39. Pereyra F., et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 2008, 197:563-571.
40. Hatano H., et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J. Virol. 2009, 83:329-335.
41. Blankson J.N., et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J. Virol. 2007, 81:2508-2518.
42. Lamine A., et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 2007, 21:1043-1045.
43. Miura T., et al. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J. Virol. 2008, 82:8422-8430.
44. Mens H., et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J. Virol. 2010, 84:12971-12981.
45. O'Connell K.A., et al. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J. Virol. 2010, 84:7018-7028.
46. Hatano H., et al. Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers. AIDS 2013, 27:2255-2260.
47. Kelesidis T., et al. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J. Infect. Dis. 2012, 206:1558-1567.
48. Sandler N.G., et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 2011, 203:780-790.
49. Hunt P.W., et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011, 25:2123-2131.
50. Kuller L.H., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008, 5:e203.
51. Hunt P.W., et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 2008, 197:126-133.
52. Hunt P.W., et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS ONE 2011, 6:e15924.
53. Krishnan S., et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. J. Infect. Dis. 2014, 209:931-939.
54. Pereyra F., et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012, 26:2409-2412.
55. Sanchez J.L., et al. Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy, but may be reversible with curative interventions. J. Infect. Dis. 2014, Published online October 24, 2014. http://dx.doi.org/10.1093/infdis/jiu586.
56. Hsue P.Y., et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009, 23:1059-1067.
57. Hatano H., et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog. 2013, 9:e1003691.
58. Chun T.W., et al. Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J. Infect. Dis. 2013, 208:1443-1447.